申请人:Novo Nordisk A/S
公开号:US07019026B1
公开(公告)日:2006-03-28
Disclosed are novel compounds, novel compositions, methods of their use, and methods of their manufacture, where such compounds of Formula 1 are pharmacologically useful inhibitors of Protein Tyrosine Phosphatases (PTPases) such as PTP1B, CD45, SHP-1, SHP-2, PTPα, LAR and HePTP or the like,
wherein n, m, X, Y, R1, R2, R3, R4, R5 and R6 are defined more fully in the description. The compounds are useful in the treatment of type I diabetes, type II diabetes, impaired glucose tolerance, insulin resistance, obesity, and other diseases.
揭示了一种新颖的化合物、新颖的组合物、它们的使用方法以及它们的制备方法,其中Formula 1的这些化合物是药理学上有用的蛋白酪氨酸磷酸酶(PTPases)抑制剂,如PTP1B、CD45、SHP-1、SHP-2、PTPα、LAR和HePTP等,其中n、m、X、Y、R1、R2、R3、R4、R5和R6在描述中有更详细的定义。这些化合物在治疗I型糖尿病、II型糖尿病、糖耐量受损、胰岛素抵抗、肥胖和其他疾病中是有用的。